- Home
- APLM vs LMFA Comparison
APLM vs LMFA Comparison
Compare APLM & LMFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- LMFA
- Stock Information
- Founded
- APLM 2016
- LMFA 2008
- Country
- APLM United States
- LMFA United States
- Employees
- APLM N/A
- LMFA N/A
- Industry
- APLM Blank Checks
- LMFA Finance: Consumer Services
- Sector
- APLM Finance
- LMFA Finance
- Exchange
- APLM Nasdaq
- LMFA Nasdaq
- Market Cap
- APLM 7.7M
- LMFA 7.0M
- IPO Year
- APLM N/A
- LMFA 2015
- Fundamental
- Price
- APLM $6.51
- LMFA $1.43
- Analyst Decision
- APLM Strong Buy
- LMFA Hold
- Analyst Count
- APLM 1
- LMFA 1
- Target Price
- APLM $200.00
- LMFA N/A
- AVG Volume (30 Days)
- APLM 57.8K
- LMFA 36.4K
- Earning Date
- APLM 04-03-2025
- LMFA 05-15-2025
- Dividend Yield
- APLM N/A
- LMFA N/A
- EPS Growth
- APLM N/A
- LMFA N/A
- EPS
- APLM N/A
- LMFA N/A
- Revenue
- APLM $198,000.00
- LMFA $10,555,948.00
- Revenue This Year
- APLM $415.15
- LMFA $0.98
- Revenue Next Year
- APLM N/A
- LMFA $4.31
- P/E Ratio
- APLM N/A
- LMFA N/A
- Revenue Growth
- APLM N/A
- LMFA N/A
- 52 Week Low
- APLM $4.71
- LMFA $1.02
- 52 Week High
- APLM $53.00
- LMFA $6.11
- Technical
- Relative Strength Index (RSI)
- APLM 49.37
- LMFA 57.42
- Support Level
- APLM $5.41
- LMFA $1.11
- Resistance Level
- APLM $6.19
- LMFA $1.50
- Average True Range (ATR)
- APLM 0.77
- LMFA 0.13
- MACD
- APLM 0.08
- LMFA 0.04
- Stochastic Oscillator
- APLM 95.24
- LMFA 85.36
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About LMFA LM Funding America Inc.
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining Operations, which generate the majority of its revenue.